Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts.
Ranjit K MehtaSanjima PalKoushik KondapiMerna SittoCuyler DewarTheresa DevasiaMatthew J SchipperDafydd G ThomasVenkatesha BasrurManjunath Amit P PaiYoshihiro MorishimaYoichi OsawaWilliam B PrattTheodore S LawrenceMukesh K NyatiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
This study shows that a significant therapeutic ratio can be achieved by a low dose of Hsp90 inhibitor in combination with radiotherapy. Hsp90 inhibition, even at a low dose, can be monitored by measuring Hsp70 expression in PBMCs in human studies.